RxAlly names Tom O'Grady to leadership team

Tuesday, July 17, 2012 12:12 PM

RxAlly, a first-of-its-kind alliance of more than 22,000 pharmacies nationwide, has named Tom O'Grady to its leadership team.  As general counsel and executive vice president of corporate development, O’Grady brings more than 30 years of corporate and transactional law experience. He will be structuring business relationships between RxAlly and the companies and businesses it will be working with as it continues to align pharmacies and pharmacists, the patients they serve and the payer community.

O'Grady joins RxAlly from McGuireWoods, where he focused on transactional law for health care and other technology-enabled companies for 26 years. Previously, he practiced in South Africa, where he became a partner in Bowman Gilfillan, one of South Africa's largest law firms. He spent a year at Wall Street law firm Shearman & Sterling.

RxAlly is a performance network of more than 22,000 member pharmacies nationwide, united to help patients achieve better health while reducing costs. RxAlly aims to improve health through personalized pharmacist care, clinical research and evidence-based clinical practices, and an interoperable technology platform.

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 2

Roche's $8.3B InterMune buy continues its buying spree with 'bolt-on' deal, fueling record M&A activity

FDA action plan seeks to close gap in women and minority patient representation in clinical trials

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs